REMARKS

Claims 2-17, 25, 29, 38, 44-61 and 65-107 remain pending.

Claims 4-9, 14-17, 25, 29, 38, 44-61, 66-73, 79-89, 98-105 and 107 have been withdrawn.

Claims 2, 65 and 106 are in independent form.

Claims 2, 3, 75-77 and 106 have been amended to correct the indefiniteness noted by the Examiner.

In Claims 2, 65 and 106, the diseases have been limited to those listed on page 2 lines 17-20 of the Specification.

Applicant respectfully points out that, contrary to Examiner's remarks on the Office Action, U.S. Patent No. 5,906,996 incorporated by reference in the Specification, contains experimental data. Moreover, the Specification cites numerous prior findings that bring support to the Claims.

It is noted that some of the withdrawn claims are dependant upon canceled ones, and will have to be amended upon allowance of the generic claims before re-incorporation in the application.

In view of the above amendment, allowance of the pending claims is earnestly solicited.

April <u>7</u>, 2005

Respectfully submitted.

John D. Buchaca

Registration No. 37,289

1545 Hotel Circle South, Suite 150

San Diego, CA 92108-3426 Telephone: 619 294 2922

Fax: 619 294 8674

AMENDMENT Serial No. 10/017,235

040316

Signature:

Date: APRIL 7 2